Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling 125,200 shares, an increase of 17.0% from the August 31st total of 107,000 shares. Approximately 4.6% of the shares of the stock are sold short. Based on an average daily volume of 37,100 shares, the days-to-cover ratio is presently 3.4 days.

Moleculin Biotech Stock Performance

Shares of Moleculin Biotech stock traded up $0.03 during trading on Monday, hitting $2.78. The company’s stock had a trading volume of 2,014 shares, compared to its average volume of 31,270. Moleculin Biotech has a 52 week low of $2.12 and a 52 week high of $15.75. The stock has a 50-day moving average price of $2.60 and a two-hundred day moving average price of $3.98.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). Sell-side analysts forecast that Moleculin Biotech will post -8.6 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Moleculin Biotech in a research report on Thursday. They set a “sell” rating on the stock.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC raised its position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 156,000 shares of the company’s stock after acquiring an additional 7,505 shares during the quarter. Armistice Capital LLC owned about 6.75% of Moleculin Biotech worth $549,000 as of its most recent SEC filing. 15.52% of the stock is currently owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.